'Reprogrammed' treatment-resistant lymphomas respond to cancer drugs
A phase I clinical trial showed diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy can be reprogrammed to respond to treatment using the drug azacitidine, according to a study published in Cancer Discovery, ...
Aug 16, 2013
0
0